心先安佐治小儿病毒性心肌炎临床疗效分析

The efficacy analysis of meglumine cyclic adenylaye for viral myocarditis in children

目的:分析心先安佐治小儿病毒性心肌炎的临床疗效。方法:136例病毒性心肌炎患儿随机分为治疗组及对照组,在相同的 基础治疗条件下,治疗组应用心先安2～5mg kg,加液静滴,每天2次。结果:心先安组;痊愈51例(75%),好转12例(17.65%),无效5例(7. 35%),总有效92.65%。对照组痊愈41例(60.29%),好转14例(20.59%),无效13例(19.12%),总有效80.88%。两组相比、差异有显著性 (x2=4.09,P<0.005)。结论:心先安治疗小儿病毒性心肌炎疗效确切,且安全、可靠。

Objective:To explore the clinical efficacy of meglumine cyclic adenylaye for viral myocarditis in children.Methods:136patients with viral myocarditis were randomly divided into meglumine cyclic adenylaye group(68patients)and control group(68patients).On basis of same therapy conditions in both groups,treatment group received meglumine cyclic adenylaye2-5mg·kg-1,iv gtt,bid.The efficacy and side effect were observed.Results:The clinical total effective rate,remarkable effective rate,effecˉtive rate and ineffective rate were92.65%,75%,17.65%and7.35%in treatment group,and those in control group were80.88%,60.29%,20.59%and19.12%,respectively.There was a very significant difference between two groups(x 2 =4.09,P<0.05 ). Conclusions:Meglumine cyclic adenylaye is obviously effective in the treatment of viral myocarditis in children.There are no obvious adverse reactions.